NCT04577885已完成1 期
A Single-center, Open, Single Does, Drug-drug Interaction Study to Investigate the Effects of Rifampin on the Pharmacokinetics of Healthy Chinese Adult Subjects After Oral Administration of SHR2554 Tablets
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameter: Cmax of SHR2554
研究概览
简要总结
The primary objective of the study is to evaluate the effect of Rifampin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR2554 tablets. The secondary objective of the study is to evaluate the safety of single-dose oral administration of SHR2554 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The informed consent is signed before the trial, and the content, process and possible adverse reactions are fully understood;
- •Be able to complete the study according to the requirements of the test scheme;
- •Healthy male and female subjects aged 18 to 45 years (including both ends) on the date of signing informed consent;
- •The body weight of male subjects is no less than 50 kg and that of female subjects is no less than 45 kg. Body mass index (BMI) is in the range of 19.0-26.0 kg/m2 (including the critical value).
排除标准
- •Participated in blood donation within 3 months before taking the study drug and donate blood ≥400 mL, or received blood transfusion;
- •Allergic constitution, including severe drug allergy or drug allergy history; allergic history of SHR2554 tablets, Rifampin, Rifamycin or their excipients;
- •People who have a history of drug and/or alcohol abuse, have a positive alcohol or drug screening test, or have a history of drug abuse in the past five years or have used drugs within 3 months before the test;
- •Smoking and alcohol addicts (drinking 14 units of alcohol per week: 1 unit = 285 ml beer, 25 ml spirits, or 100 ml wine; smoking ≥ 5 cigarettes a day) and unable to prohibit smoking and alcohol during the test period;
- •Comprehensive physical examination (vital signs, physical examination), routine laboratory examinations (blood routine, blood biochemistry, urine routine, etc.), 12-lead electrocardiogram, chest X-ray, heart color Doppler ultrasound, etc. are abnormal and have clinical significance as judged by the investigator;
- •Echocardiography suggests that the left ventricular ejection fraction (LVEF) is less than 50% or the QT interval (QTcF) corrected by Fridericia method in 12-lead ECG is ≥ 470msec;
- •A clear medical history of primary diseases of important organs such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system, etc., the investigator considers not suitable for participating in this study;
- •Those who have undergone any surgery within 6 months before screening;
- •Hepatotoxic drugs (such as Dapsone, Erythromycin, Fluconazole, Ketoconazole, Rifampin) have been taken for a long period of time (over 7 consecutive days) in the 6 months before screening;
- •Those who have taken any clinical trial drugs within 3 months;
- •Any drug that changes liver enzyme activity was taken within 28 days before taking the study drug;
- •Any prescription or over-the-counter drugs taken within 14 days before taking the study drug;
- •Ingested any vitamin products, health products or Chinese herbal medicine within 14 days before taking the study drug;
- •HCV antibody positive, HIV antibody positive, HBsAg positive, syphilis antibody positive;
- •Ingested grapefruit or products containing grapefruit, food or drink containing caffeine, xanthine or alcohol within 48 hours before taking the study drug; strenuous exercise, or other factors that affect the absorption, distribution, metabolism, and excretion of the study drug;
- •The subjects have a childbearing plan and are unwilling to take effective contraceptive measures 2 weeks before the study administration (only female subjects) and 3 months after the last administration of the drug; those who are fertile and whose serum hCG test is not negative before the study medication;
- •People with a history of fainting needles and blood, have difficulty in blood collection or cannot tolerate venipuncture blood collection;
- •Women during pregnancy and lactation;
- •Subjects with other factors not suitable to participate in this study as considered by the investigator.
研究组 & 干预措施
experimental group
Experimental
Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
干预措施: SHR2554 and Rifampin (Drug)
结局指标
主要结局
Pharmacokinetics parameter: Cmax of SHR2554
时间窗: from Day 1 to Day 13
Peak Plasma Concentration (Cmax) of SHR2554
Pharmacokinetics parameter: AUC of SHR2554
时间窗: from Day 1 to Day 13
Area under the plasma concentration versus time curve (AUC) of SHR2554
次要结局
- Other pharmacokinetics parameter: Tmax of SHR2554(from Day 1 to Day 13)
- Other pharmacokinetics parameter: T1/2 of SHR2554(from Day 1 to Day 13)
- The incidence and severity of adverse events/serious adverse events(from Day 1 to Day 13)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy SubjectsHealthy SubjectsNCT04439578Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy SubjectsAdvanced Solid TumorNCT06198556Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the BloodHealthyNCT04060719Boehringer Ingelheim16
撤回
1 期
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199Non-Hodgkin's LymphomaNCT01969682AbbVie
已完成
1 期
To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)Pharmacokinetics of Darexaban and MetabolitesHealthy SubjectsNCT01406002Astellas Pharma Inc26